Loading…
Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis
Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study...
Saved in:
| Published in: | Molecular neurobiology 2017-03, Vol.54 (2), p.1173-1186 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3 |
| container_end_page | 1186 |
| container_issue | 2 |
| container_start_page | 1173 |
| container_title | Molecular neurobiology |
| container_volume | 54 |
| creator | Rai, Vandana |
| description | Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study was to assess the risk of MTHFR C677T polymorphism for AD. Forty-one studies were identified by a search of PubMed, Google Scholar, Elsevier, and Springer Link databases, up to January 2015. Odds ratios (ORs) with corresponding 95 % confidence interval (CI) were calculated using fixed effect model or random effect model. The subgroup analyses based on ethnicity were performed. MTHFR C677T polymorphism had a significant association with susceptibility to AD in all genetic models (for T vs C OR = 1.29, 95 % CI = 1.07–1.56,
p
= 0.003; for TT + CT vs CC OR = 1.29, 95 % CI = 1.19–1.40,
p
= 0.0004; for TT vs CC OR = 1.31, 95 % CI = 1.16–1.48,
p
= 0.001; for CT vs CC OR = 1.24, 95 % CI = 1.13–1.35,
p
|
| doi_str_mv | 10.1007/s12035-016-9722-8 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877832556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4314268491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhq0K1C6FH8ClssRlezCM7fgj3FbbliK1Aq32bjnJpJslH4udHMKvx6stCCEhcZrDPO87Gj2EvOXwngOYD5ELkIoB1yw3QjB7RhZcqZxxbsULsgCbS2Z0Zi_Iqxj3AEJwMOfkQmgrQJtsQfaPOO7mFnsccQx-N1dhqIfWj0g3WE3l6CPS5eP2_m5zTdfamC39OrRzN4TDrokd9X1FV-2PHTYdBnrTRDwGNk389pF6mso9W_W-nWMTX5OXtW8jvnmel2R7d7td37OHL58-r1cPrMxAjUyCUpWuizpDbWrUucfaVFgipIX2ShkLRikhMedSCg1FVllZoPe8VEUpL8nyVHsIw_cJ4-i6JpbYtr7HYYqOW2OsFKnrP1ChtQIueULf_YXuhymkz46UtipTnItE8RNVhiHGgLU7hKbzYXYc3FGZOylzSZk7KnM2Za6em6eiw-p34pejBIgTENOqf8Lwx-l_tv4E_defoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1868545112</pqid></control><display><type>article</type><title>Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis</title><source>Springer Nature</source><creator>Rai, Vandana</creator><creatorcontrib>Rai, Vandana</creatorcontrib><description>Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study was to assess the risk of MTHFR C677T polymorphism for AD. Forty-one studies were identified by a search of PubMed, Google Scholar, Elsevier, and Springer Link databases, up to January 2015. Odds ratios (ORs) with corresponding 95 % confidence interval (CI) were calculated using fixed effect model or random effect model. The subgroup analyses based on ethnicity were performed. MTHFR C677T polymorphism had a significant association with susceptibility to AD in all genetic models (for T vs C OR = 1.29, 95 % CI = 1.07–1.56,
p
= 0.003; for TT + CT vs CC OR = 1.29, 95 % CI = 1.19–1.40,
p
= 0.0004; for TT vs CC OR = 1.31, 95 % CI = 1.16–1.48,
p
= 0.001; for CT vs CC OR = 1.24, 95 % CI = 1.13–1.35,
p
< 0.004; and for TT vs CT + CC OR = 1.13, 95 % CI = 1.00–1.28,
p
= 0.02). Results of present meta-analysis supported that the MTHFR C677T polymorphism was associated with an increased risk of AD.</description><identifier>ISSN: 0893-7648</identifier><identifier>EISSN: 1559-1182</identifier><identifier>DOI: 10.1007/s12035-016-9722-8</identifier><identifier>PMID: 26820674</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - epidemiology ; Alzheimer Disease - genetics ; Alzheimer's disease ; Biomedical and Life Sciences ; Biomedicine ; Case-Control Studies ; Cell Biology ; Genetic Predisposition to Disease - epidemiology ; Genetic Predisposition to Disease - genetics ; Humans ; Meta-analysis ; Methylenetetrahydrofolate Reductase (NADPH2) - genetics ; Neurobiology ; Neurodegeneration ; Neurology ; Neurosciences ; Polymorphism ; Polymorphism, Genetic - genetics ; Risk Factors ; Systematic review</subject><ispartof>Molecular neurobiology, 2017-03, Vol.54 (2), p.1173-1186</ispartof><rights>Springer Science+Business Media New York 2016</rights><rights>Molecular Neurobiology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3</citedby><cites>FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26820674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rai, Vandana</creatorcontrib><title>Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis</title><title>Molecular neurobiology</title><addtitle>Mol Neurobiol</addtitle><addtitle>Mol Neurobiol</addtitle><description>Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study was to assess the risk of MTHFR C677T polymorphism for AD. Forty-one studies were identified by a search of PubMed, Google Scholar, Elsevier, and Springer Link databases, up to January 2015. Odds ratios (ORs) with corresponding 95 % confidence interval (CI) were calculated using fixed effect model or random effect model. The subgroup analyses based on ethnicity were performed. MTHFR C677T polymorphism had a significant association with susceptibility to AD in all genetic models (for T vs C OR = 1.29, 95 % CI = 1.07–1.56,
p
= 0.003; for TT + CT vs CC OR = 1.29, 95 % CI = 1.19–1.40,
p
= 0.0004; for TT vs CC OR = 1.31, 95 % CI = 1.16–1.48,
p
= 0.001; for CT vs CC OR = 1.24, 95 % CI = 1.13–1.35,
p
< 0.004; and for TT vs CT + CC OR = 1.13, 95 % CI = 1.00–1.28,
p
= 0.02). Results of present meta-analysis supported that the MTHFR C677T polymorphism was associated with an increased risk of AD.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - epidemiology</subject><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer's disease</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Case-Control Studies</subject><subject>Cell Biology</subject><subject>Genetic Predisposition to Disease - epidemiology</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Methylenetetrahydrofolate Reductase (NADPH2) - genetics</subject><subject>Neurobiology</subject><subject>Neurodegeneration</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Polymorphism</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Risk Factors</subject><subject>Systematic review</subject><issn>0893-7648</issn><issn>1559-1182</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhq0K1C6FH8ClssRlezCM7fgj3FbbliK1Aq32bjnJpJslH4udHMKvx6stCCEhcZrDPO87Gj2EvOXwngOYD5ELkIoB1yw3QjB7RhZcqZxxbsULsgCbS2Z0Zi_Iqxj3AEJwMOfkQmgrQJtsQfaPOO7mFnsccQx-N1dhqIfWj0g3WE3l6CPS5eP2_m5zTdfamC39OrRzN4TDrokd9X1FV-2PHTYdBnrTRDwGNk389pF6mso9W_W-nWMTX5OXtW8jvnmel2R7d7td37OHL58-r1cPrMxAjUyCUpWuizpDbWrUucfaVFgipIX2ShkLRikhMedSCg1FVllZoPe8VEUpL8nyVHsIw_cJ4-i6JpbYtr7HYYqOW2OsFKnrP1ChtQIueULf_YXuhymkz46UtipTnItE8RNVhiHGgLU7hKbzYXYc3FGZOylzSZk7KnM2Za6em6eiw-p34pejBIgTENOqf8Lwx-l_tv4E_defoQ</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Rai, Vandana</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis</title><author>Rai, Vandana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - epidemiology</topic><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer's disease</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Case-Control Studies</topic><topic>Cell Biology</topic><topic>Genetic Predisposition to Disease - epidemiology</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Methylenetetrahydrofolate Reductase (NADPH2) - genetics</topic><topic>Neurobiology</topic><topic>Neurodegeneration</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Polymorphism</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Risk Factors</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rai, Vandana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Databases</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rai, Vandana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis</atitle><jtitle>Molecular neurobiology</jtitle><stitle>Mol Neurobiol</stitle><addtitle>Mol Neurobiol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>54</volume><issue>2</issue><spage>1173</spage><epage>1186</epage><pages>1173-1186</pages><issn>0893-7648</issn><eissn>1559-1182</eissn><abstract>Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study was to assess the risk of MTHFR C677T polymorphism for AD. Forty-one studies were identified by a search of PubMed, Google Scholar, Elsevier, and Springer Link databases, up to January 2015. Odds ratios (ORs) with corresponding 95 % confidence interval (CI) were calculated using fixed effect model or random effect model. The subgroup analyses based on ethnicity were performed. MTHFR C677T polymorphism had a significant association with susceptibility to AD in all genetic models (for T vs C OR = 1.29, 95 % CI = 1.07–1.56,
p
= 0.003; for TT + CT vs CC OR = 1.29, 95 % CI = 1.19–1.40,
p
= 0.0004; for TT vs CC OR = 1.31, 95 % CI = 1.16–1.48,
p
= 0.001; for CT vs CC OR = 1.24, 95 % CI = 1.13–1.35,
p
< 0.004; and for TT vs CT + CC OR = 1.13, 95 % CI = 1.00–1.28,
p
= 0.02). Results of present meta-analysis supported that the MTHFR C677T polymorphism was associated with an increased risk of AD.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>26820674</pmid><doi>10.1007/s12035-016-9722-8</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-7648 |
| ispartof | Molecular neurobiology, 2017-03, Vol.54 (2), p.1173-1186 |
| issn | 0893-7648 1559-1182 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1877832556 |
| source | Springer Nature |
| subjects | Alzheimer Disease - diagnosis Alzheimer Disease - epidemiology Alzheimer Disease - genetics Alzheimer's disease Biomedical and Life Sciences Biomedicine Case-Control Studies Cell Biology Genetic Predisposition to Disease - epidemiology Genetic Predisposition to Disease - genetics Humans Meta-analysis Methylenetetrahydrofolate Reductase (NADPH2) - genetics Neurobiology Neurodegeneration Neurology Neurosciences Polymorphism Polymorphism, Genetic - genetics Risk Factors Systematic review |
| title | Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A12%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylenetetrahydrofolate%20Reductase%20(MTHFR)%20C677T%20Polymorphism%20and%20Alzheimer%20Disease%20Risk:%20a%20Meta-Analysis&rft.jtitle=Molecular%20neurobiology&rft.au=Rai,%20Vandana&rft.date=2017-03-01&rft.volume=54&rft.issue=2&rft.spage=1173&rft.epage=1186&rft.pages=1173-1186&rft.issn=0893-7648&rft.eissn=1559-1182&rft_id=info:doi/10.1007/s12035-016-9722-8&rft_dat=%3Cproquest_cross%3E4314268491%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-3055d6fbf4e67fe69aef7dece00556a5578075523e9133260b4d83beaa1c5bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1868545112&rft_id=info:pmid/26820674&rfr_iscdi=true |